Potential impact of biologics and emerging therapies for psoriasis and atopic dermatitis on future fertility: Reassurance to patients but more data are needed

J Am Acad Dermatol. 2017 Oct;77(4):758-763. doi: 10.1016/j.jaad.2017.05.025.

Authors

Betty Y Kong¹, Supriya Immaneni¹, Amy S Paller¹, Shuai Xu²

Affiliations

¹ Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
² Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: stevexu@northwestern.edu.

PMID: 28917457
DOI: 10.1016/j.jaad.2017.05.025

No abstract available

Publication types

Letter
Multicenter Study

MeSH terms

Adalimumab / adverse effects
Adalimumab / therapeutic use
Adult
Biological Products / administration & dosage
Biological Products / adverse effects*
Biological Products / pharmacology
Cohort Studies
Dermatitis, Atopic / diagnosis
Dermatitis, Atopic / drug therapy*
Etanercept / adverse effects*
Etanercept / therapeutic use
Female
Humans
Infertility, Female / chemically induced*
Infertility, Female / epidemiology
Infertility, Female / physiopathology
Infertility, Male / chemically induced*
Infertility, Male / epidemiology
Infertility, Male / physiopathology
Male
Needs Assessment
Patient Safety
Psoriasis / diagnosis
Psoriasis / drug therapy*
Retrospective Studies
Risk Assessment
Risk Factors
Severity of Illness Index

Substances

Biological Products
Adalimumab
Etanercept